Marlys L Koschinsky, Archna Bajaj, Michael B Boffa, Dave L Dixon, Keith C Ferdinand, Samuel S Gidding, Edward A Gill, Terry A Jacobson, Erin D Michos, Maya S Safarova, Daniel E Soffer, Pam R Taub, Michael J Wilkinson, Don P Wilson, Christie M Ballantyne
Since the 2019 National Lipid Association (NLA) Scientific Statement on Use of Lipoprotein(a) in Clinical Practice was issued, accumulating epidemiological data have clarified the relationship between lipoprotein(a) [Lp(a)] level and cardiovascular disease risk and risk reduction. Therefore, the NLA developed this focused update to guide clinicians in applying this emerging evidence in clinical practice. We now have sufficient evidence to support the recommendation to measure Lp(a) levels at least once in every adult for risk stratification...
March 29, 2024: Journal of Clinical Lipidology